IL310975A - LOU064 for the treatment of multiple sclerosis - Google Patents

LOU064 for the treatment of multiple sclerosis

Info

Publication number
IL310975A
IL310975A IL310975A IL31097524A IL310975A IL 310975 A IL310975 A IL 310975A IL 310975 A IL310975 A IL 310975A IL 31097524 A IL31097524 A IL 31097524A IL 310975 A IL310975 A IL 310975A
Authority
IL
Israel
Prior art keywords
lou064
multiple sclerosis
treating multiple
treating
sclerosis
Prior art date
Application number
IL310975A
Other languages
English (en)
Hebrew (he)
Inventor
Souvik Bhattacharya
Bruno Bieth
Bruno Cenni
Peter End
Gordon Graham
Michael Juhnke
Rajesh Singh Karan
Allison Donna Mann
Etienne Pigeolet
Karin Rapp
Kim-Hien Sin
Huixin Yu
Ying Zhang
Original Assignee
Novartis Ag
Souvik Bhattacharya
Bruno Bieth
Bruno Cenni
Peter End
Gordon Graham
Michael Juhnke
Rajesh Singh Karan
Allison Donna Mann
Etienne Pigeolet
Karin Rapp
Sin Kim Hien
Huixin Yu
Ying Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Souvik Bhattacharya, Bruno Bieth, Bruno Cenni, Peter End, Gordon Graham, Michael Juhnke, Rajesh Singh Karan, Allison Donna Mann, Etienne Pigeolet, Karin Rapp, Sin Kim Hien, Huixin Yu, Ying Zhang filed Critical Novartis Ag
Publication of IL310975A publication Critical patent/IL310975A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • A61K9/2826Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL310975A 2021-09-03 2022-09-01 LOU064 for the treatment of multiple sclerosis IL310975A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163240444P 2021-09-03 2021-09-03
US202163282363P 2021-11-23 2021-11-23
US202263304106P 2022-01-28 2022-01-28
US202263353866P 2022-06-21 2022-06-21
US202263369008P 2022-07-21 2022-07-21
PCT/IB2022/058205 WO2023031840A1 (en) 2021-09-03 2022-09-01 Lou064 for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
IL310975A true IL310975A (en) 2024-04-01

Family

ID=83438454

Family Applications (1)

Application Number Title Priority Date Filing Date
IL310975A IL310975A (en) 2021-09-03 2022-09-01 LOU064 for the treatment of multiple sclerosis

Country Status (10)

Country Link
US (1) US20240350489A1 (https=)
EP (1) EP4395779A1 (https=)
JP (2) JP7564347B2 (https=)
KR (1) KR20240055038A (https=)
AU (1) AU2022337087A1 (https=)
CA (1) CA3229887A1 (https=)
IL (1) IL310975A (https=)
MX (1) MX2024002581A (https=)
TW (1) TW202310841A (https=)
WO (1) WO2023031840A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021398051A1 (en) 2020-12-10 2023-07-27 Principia Biopharma Inc. Crystal form of tolebrutinib, preparation method therefor and use thereof
US20260027100A1 (en) * 2022-05-13 2026-01-29 Principia Biopharma Inc. Therapeutic tyrosine kinase inhibitors for myelin oligodendrocyte glycoprotein antibody disease (mogad)
CA3260242A1 (en) * 2022-06-24 2023-12-28 Merck Patent Gmbh TREATMENT REGIMEN FOR AUTOIMMUNE AND INFLAMMATORY DISEASES
US20250243170A1 (en) * 2024-01-26 2025-07-31 Novartis Ag Remibrutinib drug substance and drug product substantially free of nitrosamine impurity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130197080A1 (en) * 2010-08-02 2013-08-01 Sanofi Use of teriflunomide for treating multiple sclerosis
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
EP3738084A4 (en) * 2018-01-08 2021-11-17 G1 Therapeutics, Inc. SUPERIOR G1T38 DOSING SCHEMES
CN117285467A (zh) * 2018-07-31 2023-12-26 罗索肿瘤学公司 喷雾干燥的分散体和制剂
RS67141B1 (sr) 2019-05-23 2025-09-30 Novartis Ag Inhibitor brutonove tirozin kinaze za upotrebu u lečenju hronične spontane urtikarije
CN113840821A (zh) 2019-05-23 2021-12-24 诺华股份有限公司 Btk抑制剂的晶型
BR112021023110A2 (pt) 2019-05-23 2022-04-12 Novartis Ag Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
WO2022081512A1 (en) * 2020-10-12 2022-04-21 Synubi Pharmaceuticals Llc Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors
MX2023008671A (es) * 2021-01-26 2023-09-25 Novartis Ag Composicion farmaceutica.
BR112023017648A2 (pt) * 2021-03-03 2023-11-14 Janssen Pharmaceutica Nv Terapia de combinação com o uso de um inibidor de malt1 e um inibidor de btk

Also Published As

Publication number Publication date
JP7564347B2 (ja) 2024-10-08
US20240350489A1 (en) 2024-10-24
JP2023542878A (ja) 2023-10-12
JP2024178420A (ja) 2024-12-24
TW202310841A (zh) 2023-03-16
EP4395779A1 (en) 2024-07-10
KR20240055038A (ko) 2024-04-26
CA3229887A1 (en) 2023-03-09
WO2023031840A1 (en) 2023-03-09
MX2024002581A (es) 2024-03-20
AU2022337087A1 (en) 2024-03-14

Similar Documents

Publication Publication Date Title
IL310975A (en) LOU064 for the treatment of multiple sclerosis
IL287907A (en) Cancer treatment methods
IL288201A (en) Dental care device
ES3064618T3 (en) Compositions for treating cancer
SG11202100682YA (en) Method for treating epilepsy
SG11202108029XA (en) Methods of treating multiple myeloma
GB2600737B (en) Robotic surface treating system
GB2600738B (en) Robotic surface treating system
IL316747A (en) Lymphoma treatment methods
GB201909468D0 (en) Compounds for treating cancer
HUE064901T2 (hu) Kezelõrendszer munkadarabok kezelésére
PL4048284T4 (pl) Metoda leczenia nowotworów
IL289824A (en) Methods of treating multiple sclerosis
IL290319A (en) Compound for combined treatment
IL284668A (en) Methods of treating schizophrenia
GB2600736B (en) Robotic surface treating system
GB2600734B (en) Robotic surface treating system
GB2600735B (en) Robotic surface treating system
GB2600739B (en) Robotic surface treating system
HUE058014T2 (hu) Kezelõberendezés munkadarabok kezeléséhez
SG11202107355RA (en) Improved method and compositions for surface treatment
HK40106430A (en) Lou064 for treating multiple sclerosis
GB202006236D0 (en) New treatment
GB201909466D0 (en) Compounds for treating cancer
GB202007652D0 (en) Compounds for treating covid-19